A sunshine act for Europe

The dark side of the sun

BMJ 2011; 343 doi: 10.1136/bmj.d7024 (Published 1 November 2011)
Cite this as: BMJ 2011;343:d7024

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Mark Wilson, director of medical ethics1,
  2. Miran Epstein, senior lecturer in medical ethics and law2
  1. 1Health Research Associates, Ottawa, ON, Canada K2B 6J4
  2. 2Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK
  1. healthresearch{at}rogers.com

The US Sunshine Act raises a cautionary note.1 Its stress on transparency as a solitary measure to tackle commercial conflicts of interest will preserve the status quo.

The act assumes that disclosure of conflicts between commercial and consumer interests entails victory of the latter over the former—this is not true. It assumes that because such disclosure is …

Access to the full text of this article requires a subscription or payment

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL